Our Board

Our experienced board provides strong oversight and governance

Mr Robert W. Duggan has served as Summit’s Chief Executive Officer since April 2020 and a member of the Board of Directors since December 2019. He is a serial US based entrepreneur who has built several successful companies across different industries, including biotechnology. Mr Duggan is currently the Chief Executive Officer of Duggan Investment Inc., a private US investment firm. Mr Duggan has served on the boards of a number of US public and private companies and he is currently chairman of the board of the Nasdaq listed company, Pulse Biosciences, Inc. He was previously a substantial shareholder in and the Chairman of the Board and Chief Executive Officer of Pharmacyclics, Inc., which was sold to AbbVie Inc., in 2015. Previously, he was the Chairman of the Board and Chief Executive Officer of Computer Motion, Inc., which later merged with Intuitive Surgical, Inc.

Mr Edwards served as Summit’s Chief Executive Officer from April 2012-2020 and a member of the Board of Directors since April 2012. Prior to joining the Company, Mr Edwards served as interim Chief Executive Officer of the BioIndustry Association, a UK trade organisation, from November 2011 to June 2012, and Chief Executive Officer at Antisoma plc, a biotechnology company specialising in the development of novel drugs for the treatment of cancer, from 1998 to 2011.

Mr Edwards also previously served as Vice President of Business Development at Therapeutic Antibodies Ltd. Mr Edwards received a BSc in biochemistry from Bristol University and a MSc in economics from the London Business School.

Mr. Erdtmann has over 25 years of experience in the investment banking and the financial industries. He currently is a Portfolio Manager and General Partner at Point Sur Investors, a biotech focused investment fund. He also serves as President and co-founder of Biomea Health, a precision oncology company creating new generations of molecular scaffolds of targeting genetically defined diseases. Prior to Biomea Health, Mr. Erdtmann was 8 years at Pharmacyclics, Inc. (NASDAQ: PCYC) and oversaw a broad range of departments while helping to grow the company from 47-634 employees. He began leading the Finance Department and managed all Accounting, SEC Reporting, Audits and Investor Relations. He also built up and ran IT, HR, Legal, Facilities and Events for the company. Later, as the Executive Vice President of Corporate Affairs, he assumed additional responsibilities for Corporate Communications. Mr. Erdtmann actively participated in the final execution of key corporate milestones for Pharmacyclics, among them the Collaboration Agreement with J&J in 2011 (value $1.0 Billion) and the merger agreement with AbbVie in 2015 (value $21 Billion). Mr. Erdtmann served on the board of PolarityTE (NASDAQ PTE), a regenerative medicine company, where he was its Audit Committee Chair until March 2020. Mr. Erdtmann began his career at Commerzbank in Germany, where he was an investment banker and portfolio manager for large institutional accounts. He earned the Diplom Kaufmann degree with honors in finance and banking from the Westfaelische Wilhelms Universitaet of Muenster, Germany, the equivalent to a US Master of Business Administration degree.

Mr Manmeet Soni has extensive experience in transitioning biotechnology companies from development stage through commercialisation and globalisation. He is currently the Chief Financial Officer and Executive Vice President of Reata Pharmaceuticals, Inc. where he is responsible for overall global functions of finance, tax, treasury, internal audit, information technology, investor relations, corporate communication and strategy functions. He has served as the Chief Financial Officer of several publicly-listed life science companies, including Pharmacyclics, Inc., where he played a vital role in the acquisition by Abbvie, Inc. for $21 billion in 2015, Ariad Pharmaceuticals Inc., where he played a major role in the acquisition by Takeda Inc. for $5.1 billion in 2017, and Alnylam Pharmaceuticals, Inc., where he raised over $2.5 billion in cash. Mr Soni currently serves on the board of Arena Pharmaceuticals, Inc. and Pulse Biosciences, Inc. He is a certified public accountant and chartered accountant from India and received his Bachelor of Commerce from Hansraj College, Delhi University, India.

Dr Ventzislav Stefanov joined our company in December of 2019 as Non-Executive Director and took an executive position in April 2020. Previously he was independent consultant providing advice, including to Duggan Investments Inc, on the therapeutic and commercial prospects of marketed and investigational antibiotics. In his previous tenures, Dr Stefanov held commercial  and marketing positions with Bayer, Merck Sharp & Dohme, AstraZeneca and Eli Lilly. He had been involved in launching and marketing across Europe several classes of antibiotics including quinolones, carbapenems, cephalosporins and vancomycin. Dr Stefanov received his MD degree from the Medical University in Sofia, Bulgaria.

Dr Elaine Stracker has over 20 years of legal experience for Fortune 500 and start-up life science companies. She currently serves as General Counsel and Senior Vice President for Corporate Development at Maky Zanganeh & Associates Inc., where she assists with due diligence, intellectual property, financings, transactional matters, HR, compliance, litigation, operations and overall strategy development. Previously, Dr Stracker served as General Counsel at Indigo Ag. and at Pharmacyclics, and has held various senior legal counsel positions at Medtronic Inc., Gilead Sciences Inc. Merck & Co., Inc. and Molecular Probes, Inc. (acquired by Invitrogen, Inc.). Dr Stracker earned both a Bachelor’s degree in chemistry and a Doctor of Philosophy degree in organic chemistry from the University of California, Davis.  In addition, she earned a Juris Doctorate degree from the Boalt School of Law at the University of California.